<DOC>
	<DOCNO>NCT02300129</DOCNO>
	<brief_summary>Phase 2a study ass efficacy safety CD07805/47 0.5 % gel prevention flush rosacea .</brief_summary>
	<brief_title>Effect CD07805/47 Gel Rosacea Flushing</brief_title>
	<detailed_description>The objective study rosacea patient ( type I &amp; II ) : - demonstrate objectively CD07805/47 0.5 % gel able prevent flush induce specific trigger ( hot water ) control condition ; - demonstrate CD07805/47 0.5 % gel able prevent flush whatever trigger everyday life condition ; - investigate reduction redness associate decrease skin sensation heat , stinging/burning , skin tension sweating ; - demonstrate efficacy transient redness sensation take place population ( rosacea type I rosacea type II ) . This single-centre , randomize , Investigator mask , placebo control study comprise follow period : A screening period maximum 4 week A one-week treatment phase ( Period 1 ) 3 session use flush model , every day . This Period 1 include cross-over design ( first third session ) split face design ( second session ) . During period , thirty six ( 36 ) subject receive site study drug follow ( order session randomize ) : - CD07805/47 placebo gel side face , - one side face treat CD07805/47 0.5 % gel , side treat CD07805/47 placebo gel ( allocation treatment half-face determine accord randomization list ) , - CD07805/47 0.5 % gel side face ; A 2-days wash-out period ( Period 1 Period 2 ) treatment either side face A 4-week treatment phase ( Period 2 ) correspond cross-over design subject apply study drug home whole face , daily 7 day per week . The subject divide 2 group eighteen ( 18 ) subject receive either CD07805/47 0.5 % gel first 2 week CD07805/47 placebo gel CD07805/47 placebo gel first 2 week CD07805/47 0.5 % gel , accord randomization . All subject take part study randomize separately two period full sequence begin clinical trial ( randomization number study ) , explain arms/groups detailed section `` Arms Interventions '' . Only primary efficacy endpoint : total number flush 2-week period detail outcome measure section . The endpoint secondary exploratory . The purpose Period 1 ass whether simpler shorter design base flush induce trigger could efficient detect prevention flush classical long design Period 2 .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Flushing</mesh_term>
	<criteria>1 . The subject male female , least 18 year age old Screening visit . 2 . The subject clinical diagnosis mild moderate erythematotelangiectatic rosacea mild moderate papulopustular rosacea accord National Rosacea Society grading ( Wilkin et al. , 2004 ) 3 . The subject least five flush episode last week Screening Baseline visit 1 . The subject particular form rosacea ( rosacea conglobata , rosacea fulminans , isolated rhinophyma , isolated pustulosis chin ) , concomitant facial dermatosis similar rosacea perioral dermatitis , demodicidosis facial keratosis pilaris , seborrheic dermatitis , acute lupus erythematosus actinic telangiectasia ; 2 . The subject current treatment monoamine oxidase inhibitor , barbiturate , opiate , sedative , systemic anesthetic , alphaagonists ; 3 . The subject le 3 month stable dose treatment tricyclic antidepressant , cardiac glycoside , beta blocker antihypertensive agent ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>